See more : Goldenwell Biotech, Inc. (GWLL) Income Statement Analysis – Financial Results
Complete financial analysis of AREV Life Sciences Global Corp. (AREVF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AREV Life Sciences Global Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- JPMorgan Claverhouse Investment Trust plc (JCH.L) Income Statement Analysis – Financial Results
- Nanjing Railway New Technology Co.,Ltd. (301016.SZ) Income Statement Analysis – Financial Results
- Changzhou Tronly New Electronic Materials Co., Ltd. (300429.SZ) Income Statement Analysis – Financial Results
- Nihon Enterprise Co.,Ltd. (4829.T) Income Statement Analysis – Financial Results
- Latin Resources Limited (LRS.AX) Income Statement Analysis – Financial Results
AREV Life Sciences Global Corp. (AREVF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.arevlifesciences.com
About AREV Life Sciences Global Corp.
AREV Life Sciences Global Corp., an integrated life science discovery company, produces and sells functional ingredients in Canada. The company's CBD-infused products, include Canna-Mulsion and NaturVax, anti- viral supplements; NaturRelax, a natural Sleep Aid; Natur Relief, an anti-inflator and pain relief product; and white label cannabis products, as well as a range of THC products, and cannabis skincare products and medicinal oils and edibles. Its ingredients are used in products that are targeted for sale in the natural health, medical, functional food, nutraceutical, sports nutrition, and bioceutical markets. In addition, the company's products address the areas of health, which include sleep deprivation, insomnia, anxiety, pain, and inflammatory conditions, as well as other specific ailments. Further, it offers nutraceutical product formulations under the Bare brand name; and ready-to-use therapeutic food products under the SUS-TAINN name. The company was formerly known as AREV NanoTec Brands Inc. and changed its name to AREV Life Sciences Global Corp. in August 2021. AREV Life Sciences Global Corp. was incorporated in 2005 and is based in Coquitlam, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 49.11K | 255.00K | 190.58K | 194.69K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 103.55K | 39.50K | 0.00 | 300.00K |
| Cost of Revenue | 19.97K | 146.45K | 148.65K | 65.56K | 52.47K | 51.58K | 7.20K | 356.00 | 44.75K | 0.00 | 0.00 | 13.12K | 11.92K | 0.00 | 112.94K |
| Gross Profit | 29.14K | 108.54K | 41.92K | 129.13K | -52.47K | -51.58K | -7.20K | -356.00 | -44.75K | 0.00 | 0.00 | 90.43K | 27.59K | 0.00 | 187.06K |
| Gross Profit Ratio | 59.33% | 42.57% | 22.00% | 66.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 87.33% | 69.84% | 0.00% | 62.35% |
| Research & Development | 84.02K | 148.33K | 128.01K | 1.15M | 195.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.99K | 133.78K |
| General & Administrative | 986.01K | 1.44M | 561.76K | 1.96M | 1.53M | 733.00K | 207.98K | 81.02K | 29.60K | 33.17K | 40.98K | 24.68K | 57.14K | 198.97K | 272.60K |
| Selling & Marketing | 205.91K | 186.21K | 5.29K | 42.98K | 108.88K | 39.79K | 10.77K | 2.03K | 0.00 | 402.00 | 7.56K | 3.53K | 252.00 | 786.00 | 9.66K |
| SG&A | 1.19M | 1.63M | 567.06K | 2.01M | 1.64M | 772.79K | 218.75K | 81.02K | 29.60K | 33.57K | 48.54K | 28.22K | 57.39K | 199.76K | 282.26K |
| Other Expenses | -1.23M | -4.63K | 0.00 | -97.38K | -41.88K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 49.11K | 1.92M | 843.72K | 3.22M | 1.69M | 824.38K | 225.95K | 81.38K | 29.85K | 33.82K | 48.79K | 28.47K | 71.93K | 238.67K | 417.18K |
| Cost & Expenses | 1.49M | 1.92M | 843.72K | 3.22M | 1.69M | 824.38K | 225.95K | 81.38K | 29.85K | 33.82K | 48.79K | 41.59K | 83.85K | 238.67K | 530.12K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.25K | 6.95K |
| Interest Expense | 6.09K | 46.23K | 58.82K | 73.22K | 40.17K | 36.63K | 25.71K | 2.20K | 305.00 | 193.00 | 159.00 | 246.00 | 916.00 | 0.00 | 911.00 |
| Depreciation & Amortization | 125.59K | 146.45K | 148.65K | 65.56K | 52.47K | 51.58K | 7.20K | 356.00 | 255.00 | 255.00 | 255.00 | 255.00 | 255.00 | 915.00 | 1.14K |
| EBITDA | -1.31M | -797.63K | -504.49K | -3.05M | -1.64M | -797.45K | -218.75K | -81.60K | -29.60K | -33.57K | -48.54K | 62.21K | -44.09K | -249.50K | -228.98K |
| EBITDA Ratio | -2,672.26% | -596.16% | -264.72% | -1,520.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 60.08% | -111.62% | 0.00% | -76.33% |
| Operating Income | -1.39M | -1.67M | -653.14K | -3.03M | -1.69M | -849.03K | -225.95K | -81.96K | -29.85K | -33.82K | -48.79K | 61.96K | -44.35K | -250.41K | -230.12K |
| Operating Income Ratio | -2,827.74% | -653.59% | -342.72% | -1,554.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 59.84% | -112.27% | 0.00% | -76.71% |
| Total Other Income/Expenses | -55.32K | 652.97K | -395.74K | -166.66K | -6.74M | -224.58K | -25.71K | -2.20K | -13.02K | -193.00 | -159.00 | -246.00 | 27.83K | 24.46K | 6.04K |
| Income Before Tax | -1.44M | -990.31K | -1.05M | -3.19M | -8.43M | -1.02M | -251.66K | -84.16K | -75.22K | -34.02K | -48.95K | 61.71K | -16.51K | -225.95K | -224.08K |
| Income Before Tax Ratio | -2,940.37% | -388.36% | -550.37% | -1,639.99% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 59.60% | -41.80% | 0.00% | -74.69% |
| Income Tax Expense | 0.00 | 46.23K | 58.82K | 73.22K | 40.17K | 11.97K | 0.00 | 0.00 | 305.00 | 0.00 | 0.00 | 0.00 | 916.00 | -12.72K | 0.00 |
| Net Income | -1.44M | -990.31K | -1.05M | -3.19M | -8.43M | -1.02M | -251.66K | -84.16K | -75.22K | -34.02K | -48.95K | 61.71K | -16.51K | -225.95K | -224.08K |
| Net Income Ratio | -2,940.37% | -388.36% | -550.37% | -1,639.99% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 59.60% | -41.80% | 0.00% | -74.69% |
| EPS | -0.05 | -0.05 | -0.07 | -0.36 | -1.47 | -0.42 | -24.40 | -16.45 | -13.07 | -6.23 | -7.57 | 9.75 | -2.80 | -38.28 | -37.97 |
| EPS Diluted | -0.05 | -0.05 | -0.07 | -0.36 | -1.47 | -0.42 | -24.40 | -16.45 | -13.07 | -6.23 | -7.57 | 9.75 | -2.80 | -38.28 | -37.97 |
| Weighted Avg Shares Out | 30.07M | 19.59M | 15.36M | 8.96M | 5.73M | 2.42M | 10.31K | 5.12K | 5.76K | 5.46K | 6.47K | 6.33K | 5.90K | 5.90K | 5.90K |
| Weighted Avg Shares Out (Dil) | 30.07M | 19.59M | 15.36M | 8.96M | 5.73M | 2.42M | 10.31K | 5.12K | 5.76K | 5.46K | 6.47K | 6.33K | 5.90K | 5.90K | 5.90K |
AREV Signs Definitive Collaborative Development Agreement with Voynich Biosciences and Invites Richard van Breemen PhD to SAB
AREV Announces Brian Cameron as Chief Financial Officer
AREV Signs Definitive Collaborative Development Agreement with Voynich Biosciences and Invites Richard van Breemen PhD to SAB
Data Presented at the 11th IAS Conference on HIV Science Supports AREV's Development of SUS-TAINN™, a Ready-to-Use Therapeutic Food to Treat Global Malnutrition and Starvation
AREV Annual and Special General Meeting Results
AREV Expands Operations to Rochester New York Establishing Wholly Owned U.S. Subsidiary, AREV Life Sciences, Inc.
AREV Completes Land Survey and Soil Analysis for Cultivation of Mushrooms and Moringa and Prepares for Mass Production of Plant-Based Proteins For Use in Its Ready-To-Use Therapeutic Foods
AREV CEO Michael Withrow Buys 900,000 Shares of Company Stock
AREV Engages Dr. Harold C. Smith to Join Scientific Advisory Board
AREV Life Sciences Expands its Extraction Results to Clinical Characterization of Compounds, Development of Advanced-Stage Therapeutic Foods and Discovery of Plant-Based Drugs
Source: https://incomestatements.info
Category: Stock Reports